ENLIVEN THERAPEUTICS INC
ELVNNASDAQπ #1482 by market capEarnings Mar 1 Β· PostUS Equity
$46.41β
Last available close Β· quote unavailableTrack ELVN
Get earnings, price moves & breaking news on Telegram
24hβ
7dβΌ 4.9%
14dβΌ 6.3%
30dβ² 11.8%
ytdβ² 201.6%
1yβ² 113.6%
π¦Market Cap
$3.42B
Small Cap
πRevenue Growth (YoY)
0.0%
Slowing
πGross Margin
0.0%
Thin
π΅FCF Margin
0.0%
Thin
βοΈP/S Ratio
0.0x
Cheap
Otter Score
56
Fair
Trading Snapshot
- Day Range
- β
- 52-Week Range
- $14.79 β $62.32
- Volume (shares)
- β
- Avg Volume (shares)
- β
- Shares Outstanding
- 73.6M
- Next Earnings
- 2027-03-01
Fundamentals Snapshot
- Annual Revenue
- β
- Last Q Revenue
- β
- P/E Ratio
- -27.7
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-1.46
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +13.7%
ENLIVEN THERAPEUTICS INC
ELVNFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isnβt profitable yet.
β$120Mβ² +14.4% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
β$70MβΌ β3.8% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing ownerβs slice.
56.7Mβ² +13.7% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$98MβΌ β$26M YoY
About ENLIVEN THERAPEUTICS INC
Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, also a small molecule kinase inhibitor, has begun a Phase 1 clinical assessment for individuals with cancers exhibiting an abnormal HER2 gene. The company's base of operations is located in Boulder, Colorado.
π¦¦
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)πQualityβ
β
β
β
β
πGrowthβ
β
β
β
β
βοΈValuationβ
β
β
β
β
β‘Momentumβ
β
β
β
β
π§Dilutionβ
β
β
β
β
Overall Score
Fair
56/100
Analyst data unavailable.
Latest News & Updates
News unavailable.